Read by QxMD icon Read

Journal of Thoracic Oncology

David R Gandara, Joachim von Pawel, Julien Mazieres, Richard Sullivan, Åslaug Helland, Ji-Youn Han, Santiago Ponce Aix, Achim Rittmeyer, Fabrice Barlesi, Toshio Kubo, Keunchil Park, Jerome Goldschmidt, Mayank Gandhi, Cindy Yun, Wei Yu, Christina Matheny, Pei He, Alan Sandler, Marcus Ballinger, Louis Fehrenbacher
INTRODUCTION: Cancer immunotherapy may alter tumor biology such that treatment effects can extend beyond radiographic progression. In the randomized, Phase III OAK study of atezolizumab (anti-PD-L1) versus docetaxel in advanced non-small cell lung cancer, overall survival (OS) benefit with atezolizumab was observed in the overall patient population, without improvement in objective response rate (ORR) or progression-free survival (PFS). We examine the benefit-risk of atezolizumab treatment beyond progression (TBP)...
September 11, 2018: Journal of Thoracic Oncology
Thomas Yang Sun, Xiaomin Niu, Amit Chakraborty, Joel W Neal, Heather A Wakelee
No abstract text is available yet for this article.
September 11, 2018: Journal of Thoracic Oncology
Yoohwa Hwang, Chang Hyun Kang, Samina Park, Hyun Joo Lee, In Kyu Park, Young Tae Kim, Geun Dong Lee, Hyeong Ryul Kim, Se Hoon Choi, Yong-Hee Kim, Dong Kwan Kim, Seung-Il Park, Sumin Shin, Jong Ho Cho, Hong Kwan Kim, Yong Soo Choi, Jhingook Kim, Jae Il Zo, Young Mog Shim, Chang Young Lee, Jin Gu Lee, Dae Joon Kim, Hyo Chae Paik, Kyung Young Chung
INTRODUCTION: Surgical resection is a standard treatment for thymic malignancies. However, prognostic significance of nodal metastases and lymph node dissection remains unclear. The aim of this study is to determine prognostic significance of nodal metastases and role of lymph node dissection (LND) in thymic malignancies. METHODS: Between 2000 and 2013, 1,597 patients who underwent thymectomy due to thymic malignancy were included. Predictive factors for nodal metastasis and prognostic significance of LND were evaluated...
September 11, 2018: Journal of Thoracic Oncology
Léonie Ferrer, Matteo Giaj Levra, Marie Brevet, Martine Antoine, Julien Mazieres, Giulio Rossi, Rita Chiari, Virginie Westeel, Michel Poudenx, Jacques Letreut, Radj Gervais, Giorgia Osman, Nicolas Girard, Anne Claire Toffart, Silvia Novello, Denis Moro-Sibilot
Histological transformation from Non-small cell lung cancer (NSCLC) to SCLC is a mechanism of resistance in EGFR-mutant tumors but is also occasionally observed in non-mutated NSCLC. PATIENTS AND METHODS: We performed a multicenter retrospective collection of cases presenting between 2005 and 2017. The objectives were to analyse survival data and to define epidemiological, clinical, treatment and histo-molecular characteristics at both the time of diagnosis of NSCLC and of SCLC. RESULTS: Forty-eight EGFR-mutant NSCLC and 13 non-EGFR-mutant cases were registered...
September 11, 2018: Journal of Thoracic Oncology
Jessica J Lin, Emily Chin, Beow Y Yeap, Lorin A Ferris, Vashine Kamesan, Inga T Lennes, Lecia V Sequist, Rebecca S Heist, Mari Mino-Kenudson, Justin F Gainor, Alice T Shaw
INTRODUCTION: Immune checkpoint inhibitors (ICIs) are standard therapies in advanced non-small-cell lung cancer (NSCLC). While genotype-directed tyrosine kinase inhibitors (TKIs) represent the standard of care for subsets of oncogene-driven NSCLC, patients may receive ICIs during their disease course. The impact of sequential ICI/TKI therapy on the risk of hepatotoxicity has not been described. METHODS: Patients with advanced ALK/ROS1/MET-driven NSCLC treated with crizotinib, with or without preceding ICI, were identified...
September 8, 2018: Journal of Thoracic Oncology
Lars-Arne Berger, Melanie Janning, Janna-Lisa Velthaus, Isabel Ben-Batalla, Stefanie Schatz, Markus Falk, Peter Iglauer, Ronald Simon, Ru Cao, Claudio Forcato, Nicolò Manaresi, Kelli Bramlett, Genny Buson, Annkathrin Hanssen, Markus Tiemann, Guido Sauter, Carsten Bokemeyer, Sabine Riethdorf, Martin Reck, Klaus Pantel, Harriet Wikman, Sonja Loges
No abstract text is available yet for this article.
September 8, 2018: Journal of Thoracic Oncology
Koji Kameda, Takashi Eguchi, Shaohua Lu, Yang Qu, Kay See Tan, Kyuichi Kadota, Prasad S Adusumilli, William D Travis
INTRODUCTION: The eighth edition of the tumor, node, and metastasis (TNM) staging system included the proposal that the T descriptor be determined according to the invasive component, excluding lepidic component, for nonmucinous lung adenocarcinomas. We sought to conduct a clinicopathologic comparative analysis of the newly proposed classification using invasive size versus total tumor size. METHODS: Patients who underwent lung resection for primary lung adenocarcinoma with pathologic stage (p-Stage) I-IIA (based on total size [t]) were reviewed (n=1704)...
September 6, 2018: Journal of Thoracic Oncology
Clotilde Descarpentries, Frédéric Leprêtre, Fabienne Escande, Zoulika Kherrouche, Martin Figeac, Shéhérazade Sebda, Simon Baldacci, Valérie Grégoire, Philippe Jamme, Marie-Christine Copin, David Tulasne, Alexis B Cortot
INTRODUCTION: Genomic alterations affecting splice sites of MET exon 14 were recently identified in non-small cell lung cancer (NSCLC) patients. Objective responses to MET tyrosine kinase inhibitors have been reported in these patients. Thus, detection of MET exon 14 splice site mutations represents a major challenge. So far, most of these alterations were found by full-exome sequencing or large capture-based NGS panels, which are not suitable for routine diagnosis. METHODS: Aiming to provide a molecular testing method applicable in routine practice, we first developed a fragment-length analysis for detecting deletions in introns flanking MET exon 14...
September 6, 2018: Journal of Thoracic Oncology
Ben Wr Balzer, Christine Loo, Craig R Lewis, Toby N Trahair, Antoinette C Anazodo
INTRODUCTION: Primary lung cancer is extremely rare in children. It often presents with metastatic disease and carries a poor prognosis. Adenocarcinoma is the most common type of bronchogenic carcinoma in children and adults. Our aim was to systematically review the presenting features, approach to diagnosis and management, as well as the outcomes of primary pediatric adenocarcinoma of the lung. MATERIALS AND METHODS: This systematic review was prospectively registered with PROSPERO...
September 4, 2018: Journal of Thoracic Oncology
Weiye Deng, Ting Xu, Yifan Wang, Yujin Xu, Xiangyu Liu, Yu Zhao, Pei Yang, Zhongxing Liao
INTRODUCTION: The positive/resected lymph node ratio (LNR) predicts survival in many cancers, but little information is available on its value for patients with N2 NSCLC who receive PORT after resection. We tested the applicability of prognostic scoring models and heat mapping to predict overall survival (OS) and cancer-specific survival (CSS) in patients with resected N2 non-small cell lung cancer (NSCLC) and postoperative radiotherapy (PORT). METHODS: Our test cohort comprised patients identified from the Surveillance, Epidemiology, and End Results (SEER) database with N2 NSCLC who received resection and PORT in 2000-2014...
September 4, 2018: Journal of Thoracic Oncology
Jennifer Le-Rademacher, Suzanne Dahlberg, J Jack Lee, Alex A Adjei, Sumithra J Mandrekar
Treatment for lung cancer has evolved in the past three decades starting with platinum-based chemotherapy as the standard of care, regardless of histology, in the early 1990s to the current age of biomarker-driven therapy. Consequently, clinical trials in lung cancer have evolved in response to this new shift of paradigm, leading to novel approaches that simultaneously shorten the development process and allow evaluation of multiple patient cohorts. Herein, we provide an overview of the landscape of lung cancer clinical trials in the era of targeted therapies, precision medicine, and biomarkers...
September 4, 2018: Journal of Thoracic Oncology
Alex A Adjei
This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at
August 26, 2018: Journal of Thoracic Oncology
Xavier Mignard, Anne-Marie Ruppert, Martine Antoine, Julie Vasseur, Nicolas Girard, Julien Mazières, Denis Moro-Sibilo, Vincent Fallet, Nathalie Rabbe, Françoise Thivolet-Bejui, Isabelle Rouquette, Sylvie Lantuejoul, Alexis Cortot, Raphaël Saffroy, Jacques Cadranel, Antoinette Lemoine, Marie Wislez
BACKGROUND: Mesenchymal-to-epithelial transition (MET) abnormalities like amplification and exon 14 mutations may be responsive to targeted therapies. They are prevalent in lung sarcomatoid carcinomas (LSCs) and must be diagnosed as efficiently as possible. Hypothetically, c-MET overexpression by immunohistochemistry (IHC) may prove effective as a screening test for MET abnormalities. MATERIAL AND METHODS: Tissue samples were obtained from consecutive patients with a resected LSC, in four oncologic centers...
August 24, 2018: Journal of Thoracic Oncology
Massimo Moro, Elisa Caiola, Monica Ganzinelli, Elisabetta Zulato, Eliana Rulli, Mirko Marabese, Giovanni Centonze, Adele Busico, Ugo Pastorino, Filippo G de Braud, Claudio Vernieri, Michele Simbolo, Emilio Bria, Aldo Scarpa, Stefano Indraccolo, Massimo Broggini, Gabriella Sozzi, Marina Chiara Garassino
PURPOSE: we hypothesized that activating KRAS mutations and inactivation of the LKB1 oncosuppressor can cooperate to sustain NSCLC aggressiveness. We also hypothesized that the growth advantage of KRAS/LKB1 co-mutated tumors could be balanced by higher sensitivity to metabolic stress conditions, such as metformin treatment, thus revealing new strategies to target this aggressive NSCLC subtype. EXPERIMENTAL DESIGN: we retrospectively determined the frequency and prognostic value of KRAS/LKB1 co-mutations in tissue specimens from NSCLC patients enrolled in the TAILOR trial...
August 24, 2018: Journal of Thoracic Oncology
Yannis Metaxas, Gareth Rivalland, Dirk Klingbiel, Steven Kao, Sabine Schmid, Anna K Nowak, Oliver Gautschi, Tammo Bartnick, Brett G Hughes, Hasna Bouchaab, Sacha Rothschild, Nick Pavlakis, Sybille Wolleb, Ulf Petrausch, Kenneth O'Byrne, Patrizia Froesch, Melanie Löffler-Baumann, Susanne Pratsch-Peter, Prudence Russell, Walter Mingrone, Spasenija Savic, Bibhusal Thapa, Martin Früh, Miklos Pless, Roger von Moos, Laetitia Mauti, Thomas John
No abstract text is available yet for this article.
August 21, 2018: Journal of Thoracic Oncology
Hossein Borghaei, Corey J Langer, Shirish Gadgeel, Vassiliki A Papadimitrakopoulou, Amita Patnaik, Steven F Powell, Ryan D Gentzler, Renato G Martins, James P Stevenson, Shadia I Jalal, Amit Panwalkar, James Chih-Hsin Yang, Matthew Gubens, Lecia V Sequist, Mark M Awad, Joseph Fiore, Sanatan Saraf, Steven Keller, Leena Gandhi
INTRODUCTION: Cohort G of KEYNOTE-021 (NCT02039674) evaluated the efficacy and safety of pembrolizumab plus pemetrexed-carboplatin (PC) versus PC alone as first-line therapy for advanced nonsquamous NSCLC. At the primary analysis (median follow-up, 10.6 months), pembrolizumab significantly improved objective response rate (ORR) and progression-free survival (PFS); hazard ratio (HR) for overall survival (OS) was 0.90 (95% CI, 0.42‒1.91). Herein, we present an updated analysis. METHODS: 123 patients with previously untreated stage IIIB/IV nonsquamous NSCLC without EGFR/ALK aberrations were randomized 1:1 to 4 cycles of PC with/without pembrolizumab 200 mg Q3W...
August 20, 2018: Journal of Thoracic Oncology
Claire Merveilleux du Vignaux, Eric Dansin, Laurent Mhanna, Laurent Greillier, Eric Pichon, Mallorie Kerjouan, Christelle Clement-Duchene, Bertrand Mennecier, Virginie Westeel, Marie Robert, Xavier Quantin, Gérard Zalcman, Luc Thiberville, Hervé Lena, Thierry Molina, Fabien Calcagno, Pierre Fournel, Julien Mazieres, Benjamin Besse, Nicolas Girard
BACKGROUND: Thymic epithelial tumors (TET) are rare malignancies that may be aggressive and difficult to treat. In the advanced setting, systemic treatments may be delivered as primary therapy before surgery or definitive radiotherapy, as exclusive treatment when no focal treatment is feasible, or in the setting of recurrences. RYTHMIC is the nationwide network for TET in France. The objective of the study was to describe the modalities and analyze the efficacy of systemic treatments for patients with advanced TET included in the RYTHMIC prospective database hosted by the French Thoracic Cancer Intergroup (IFCT)...
August 20, 2018: Journal of Thoracic Oncology
Raphael Bueno, Isabelle Opitz
Surgical intervention plays an important role in the diagnosis, staging and treatment of malignant pleural mesothelioma (MPM) and can be applied with curative or palliative intent. The overall aim of surgery should be, as in any oncologic surgery, the macroscopic complete resection (MCR) of the tumor. Most importantly, the majority of patients with the diagnosis of MPM should be appropriately staged and initially evaluated in a multidisciplinary setting, including medical oncology, radiation oncology, and surgery after histological diagnosis...
August 16, 2018: Journal of Thoracic Oncology
Naoya Miyashita, Masafumi Horie, Hiroshi I Suzuki, Masahito Yoshihara, Dijana Djureinovic, Johan Persson, Hans Brunnström, Cecilia Lindskog, Hedvig Elfving, Patrick Micke, Akira Saito, Takahide Nagase
A subgroup of lung adenocarcinoma shows neuroendocrine differentiation and expression of achaete-scute complex homolog 1 (ASCL1), common to high-grade neuroendocrine tumors, small cell lung cancer and large cell neuroendocrine carcinoma. The aim of this study was to characterize clinical and molecular features of ASCL1-positive lung adenocarcinoma by utilizing recent transcriptome profiling in multiple patient cohorts and genome-wide epigenetic profiling including data from The Cancer Genome Atlas (TCGA). The ASCL1-positive subtype of lung adenocarcinoma developed preferentially in current or former smokers and usually did not harbor epidermal growth factor receptor (EGFR) mutations...
August 16, 2018: Journal of Thoracic Oncology
Smadar Laufer-Geva, Anna Belilovski Rozenblum, Tal Twito, Roxana Grinberg, Addie Dvir, Lior Soussan-Gutman, Maya Ilouze, Laila C Roisman, Elizabeth Dudnik, Alona Zer, Ofer Rotem, Richard B Lanman, Nir Peled
INTRODUCTION: Next-generation sequencing (NGS) of cell-free circulating tumor DNA (cfDNA) enables non-invasive genomic analysis of non-small cell lung cancer (NSCLC) patients. Although plasma-detected genomic alterations (GAs) have been shown to predict targeted therapy response, evidence of durability of response is lacking or limited to small cohorts as is the impact of cfDNA NGS results on clinical decisions. METHODS: This retrospective study of stage IIIB/IV NSCLC patients between the years 2014-2017 in Israel utilized cfDNA NGS (Guardant360) to identify targetable GAs...
August 16, 2018: Journal of Thoracic Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"